- Home
- TDTH vs APLT Comparison
TDTH vs APLT Comparison
Compare TDTH & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDTH
- APLT
- Stock Information
- Founded
- TDTH 2014
- APLT 2016
- Country
- TDTH Singapore
- APLT United States
- Employees
- TDTH N/A
- APLT N/A
- Industry
- TDTH
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- TDTH
- APLT Health Care
- Exchange
- TDTH NYSE
- APLT Nasdaq
- Market Cap
- TDTH 42.7M
- APLT 37.5M
- IPO Year
- TDTH 2024
- APLT 2019
- Fundamental
- Price
- TDTH $0.22
- APLT $0.40
- Analyst Decision
- TDTH
- APLT Buy
- Analyst Count
- TDTH 0
- APLT 7
- Target Price
- TDTH N/A
- APLT $6.10
- AVG Volume (30 Days)
- TDTH 1.2M
- APLT 1.9M
- Earning Date
- TDTH 05-25-2025
- APLT 05-20-2025
- Dividend Yield
- TDTH N/A
- APLT N/A
- EPS Growth
- TDTH N/A
- APLT N/A
- EPS
- TDTH N/A
- APLT N/A
- Revenue
- TDTH $465,435.00
- APLT $455,000.00
- Revenue This Year
- TDTH N/A
- APLT $1,768.13
- Revenue Next Year
- TDTH N/A
- APLT $361.28
- P/E Ratio
- TDTH N/A
- APLT N/A
- Revenue Growth
- TDTH N/A
- APLT N/A
- 52 Week Low
- TDTH $0.20
- APLT $0.30
- 52 Week High
- TDTH $4.74
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- TDTH N/A
- APLT 46.92
- Support Level
- TDTH N/A
- APLT $0.39
- Resistance Level
- TDTH N/A
- APLT $0.44
- Average True Range (ATR)
- TDTH 0.00
- APLT 0.04
- MACD
- TDTH 0.00
- APLT 0.01
- Stochastic Oscillator
- TDTH 0.00
- APLT 45.49
About TDTH TRIDENT DIGITAL TECH HOLDINGS LTD SPON ADS EACH REP 8 ORD CL B
Trident Digital Tech Holdings is principally engaged in the provision of business consulting service and IT customization solutions in the Republic of Singapore.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.